<DOC>
	<DOC>NCT02367781</DOC>
	<brief_summary>This randomized Phase III, multicenter, open-label study is designed to evaluate the safety and efficacy of Atezolizumab (MPDL3280A) in combination with carboplatin + Nab-paclitaxel compared with treatment with carboplatin + Nab-paclitaxel in chemotherapy-naive patients with Stage IV non-squamous non-small cell lung cancer (NSCLC).</brief_summary>
	<brief_title>A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer [IMpower 130]</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>18 years of age or older Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Histologically or cytologically confirmed, treatmentnaive Stage IV nonsquamous NSCLC Measurable disease, as defined by RECIST v1.1 Previously obtained archival tumor or tissue obtained from a biopsy at screening Adequate hematologic and end organ function Active or untreated central nervous system (CNS) metastases Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome Pregnant or lactating women History of autoimmune disease History of idiopathic pulmonary fibrosis, organizing pneumonia, druginduced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted Positive test for Human Immunodeficiency Virus (HIV) Active hepatitis B or hepatitis C Prior treatment with CD137 agonists or immune checkpoint blockade therapies, antiPD1, and antiPDL1 therapeutic antibody Severe infection within 4 weeks prior to randomization Significant history of cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>